Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study by Herrera, L. (Lizbeth) et al.
ORIGINAL ARTICLE
Risk of atrial fibrillation among bisphosphonate users:
a multicenter, population-based, Italian study
L. Herrera & I. Leal & F. Lapi & M. Schuemie & V. Arcoraci & F. Cipriani & E. Sessa &
A. Vaccheri & C. Piccinni & T. Staniscia & A. Vestri & M. Di Bari & G. Corrao &
A. Zambon & D. Gregori & F. Carle & M. Sturkenboom & G. Mazzaglia & G. Trifiro
Received: 11 February 2014 /Accepted: 23 December 2014 /Published online: 10 March 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Summary Bisphosphonate treatment is used to prevent bone
fractures. A controversial association of bisphosphonate use
and risk of atrial fibrillation has been reported. In our study,
current alendronate users were associated with a higher risk of
atrial fibrillation as compared with those who had stopped
bisphosphonate (BP) therapy for more than 1 year.
Introduction Bisphosphonates are widely used to prevent
bone fractures. Controversial findings regarding the as-
sociation between bisphosphonate use and the risk of
atrial fibrillation (AF) have been reported. The aim of
this study was to evaluate the risk of AF in association with
BP exposure.
Methods We performed a nested case-control study using the
databases of drug-dispensing and hospital discharge diagnoses
from five Italian regions. The data cover a period ranging from
July 1, 2003 to December 31, 2006. The study population
comprised new users of bisphosphonates aged 55 years and
older. Patients were followed from the first BP prescription
until an occurrence of an AF diagnosis (index date, i.e., ID),
cancer, death, or the end of the study period, whichever came
first. For the risk estimation, any AF case was matched by age
and sex to up to 10 controls from the same source population.
A conditional logistic regression was performed to obtain the
odds ratio with 95 % confidence intervals (CI). The BP expo-
sure was classified into current (<90 days prior to ID), recent
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(91–180), past (181–364), and distant past (≥365) use, with the
latter category being used as a reference point. A subgroup
analysis by individual BP was then carried out.
Results In comparison with distant past users of BP, current
users of BP showed an almost twofold increased risk of AF:
odds ratio (OR)=1.78 and 95 % CI=1.46–2.16. Specifically,
alendronate users were mostly associated with AF as compared
with distant past use of BP (OR, 1.97; 95 % CI, 1.59–2.43).
Conclusion In our nested case-control study, current users of
BP are associated with a higher risk of atrial fibrillation as
compared with those who had stopped BP treatment for more
than 1 year.
Keywords Alendronate . Atrial fibrillation .
Bisphosphonates . Nested case-control study
Introduction
Bisphosphonates are the most widely prescribed drugs for the
treatment of osteoporosis worldwide [1, 2]. These drugs in-
hibit osteoclastic bone resorption, thus increasing bone densi-
ty and reducing the risk of fractures [3, 4]. Bisphosphonates
available on the market include alendronate, risedronate, eti-
dronate, ibandronate, and the more recently marketed zoledro-
nic acid [5–7]. On the whole, bisphosphonates are safe, al-
though their use is limited by several adverse effects such as
gastrointestinal disturbances, musculoskeletal pain, and acute
phase reactions. More severe adverse reactions such as
osteonecrosis of the jaw (ONJ), hypersensitivity, kidney dis-
orders, and emerging safety signals such as atrial fibrillation
(AF) have been rarely observed [6, 8, 9]. In particular, AF has
been detected as a potential signal of intravenous zoledronic
acid and oral alendronate treatment in postmenopausal women
[10–13]. According to Cummings [14], parenteral administra-
tion of bisphosphonates may increase the release of inflam-
matory cytokines which have been associated with AF.
The HORIZON (Health Outcomes and Reduced Incidence
with Zoledronic Acid Once Yearly) study showed an in-
creased risk of serious AF in patients receiving a yearly infu-
sion of zoledronic acid when compared with a placebo (50 vs.
20 patients; p<0.001) [12, 15]. In the FIT (Fracture
Intervention Trial) study, a trend towards an increased risk of
AF with the use of alendronate compared to that of a placebo
was observed, although this finding did not exhibit the statis-
tical significance (relative risk, 1.14; 95 % confidence inter-
vals (CI), 0.83–1.57) [14, 16]. Furthermore, a few population-
based case-control studies reported controversial results
concerning the association between use of alendronic acid
and AF risk [11–13, 17–21]. In light of the current scientific
evidence, the US Food and Drug Administration (FDA) noted
that no firm conclusions could be drawn concerning relation-
ships between AF and bisphosphonate treatment [22].
AF is considered the most important type of cardiac ar-
rhythmia in the elderly population, and it is a potential trigger
for fatal strokes, thromboembolism, and worsening heart fail-
ure. The known risk factors of AF are heart failure, diabetes,
hypertension, myocardial infarction, and smoking, among
others [23–26], and given the frequency and clinical relevance
of AF, further studies are urgently needed to verify whether
bisphosphonate (BP) use may truly represent a risk factor for
AF. No studies of the relationship between BP use and AF
onset have been conducted thus far in Italy. Accordingly, the
aim of this population-based database study was an assess-
ment of the association of bisphosphonate use with AF risk
in Italian adults aged 55 years or more, by employing a nested
case-control study in a cohort of new users of BP.
Methods
Data sources
Data for this study were obtained from the Bisphosphonates
Efficacy-Safety Trade-off (BEST), a multicenter observation-
al study sponsored by the Italian Pharmaceutical Agency
(Agenzia Italiana del Farmaco, AIFA), whose design and pri-
mary results have been published previously [27]. The data
sources were outpatient drug-dispensing and hospital dis-
charge diagnoses from ten local health authorities (LHAs) in
five Italian regions, which covered a population of about 18
million citizens from July 1, 2003 to December 31, 2006. In
this database network, drug dispensing is coded according to
the Anatomical Therapeutic Chemical (ATC) classification
system, while hospital discharge diagnoses are coded using
the International Classification Disease 9th version-Clinical
Modification (ICD-CM). Fully anonymous patient-level data
from participating centers were combined in a unique central
data warehouse, and the ethical committee of each participat-
ing LHA approved the study.
Cohort selection
People aged 55 years and over with at least one BP prescrip-
tion during the study period were recruited, and the date of
their first dose was used as their entry into the study. Only new
users (with no previous prescription of BP within a 6-month
period prior to entry in the study) were included.
Subjects with a history of hospitalization due to malignant
neoplasm (ICD-9: 140 to 208) or atrial fibrillation (ICD-9:
427.31) at study entry were excluded (Fig. 1), and each patient
was followed from the study entry date until the occurrence of
AF, cancer, death, or the end of the study period (December
31, 2006), whichever came first.
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Study design
A case-control study nested in a cohort of new users of BPwas
performed in order to assess the risk of AF with BP use. All
analyses were specified a priori in the study protocol.
Case and control definitions
A case was defined as a person with a primary discharge
diagnosis of incidental AF (ICD-9: 427.31) during the study
period. The date of a diagnosis of AF was considered as the
index date (ID), and every case was matched with up to ten
controls from the same cohort by age, sex, and time of cohort
entry. Controls were selected using incidence density sam-
pling. In general, this method consists of matching each case
to a sample of those who are at risk at the time of case occur-
rence [28]. The index date of the controls was the same as
those for the matched cases.
Exposure assessment
The area of interest included all BP marketed in Italy (ATC:
M05BA* and M05BB*). The duration of exposure for each
prescription was calculated by dividing the total amount of the
drug dispensed by the defined daily drug specific dose
(DDD). Three mutually exclusive categories were defined ac-
cording to the temporal proximity of BP use: current use, if the
estimated exposure to BP covered the index date or ended
within 90 days prior to ID (i.e., carry-over period) [18]; recent
use, if the exposure to BP ended between 91 and 180 days
prior to ID; and past use, if the exposure to BP ended 181 and
365 days prior to ID. In addition, distant past use was used as
reference category for all the analyses, if the exposure to BP
had ended more than 365 days prior to ID.
Covariates
Known risk factors for AF were identified by searching
among primary/secondary hospital discharge diagnoses or
drug prescriptions. The presence of the following potential
risk factors was evaluated for any period prior to ID: myocar-
dial infarction, angina pectoris (defined by diagnosis or use of
nitrates), heart failure, diabetes mellitus (defined by diagnosis
or use of hypoglycemic drugs), hyperthyroidism, and prior use
of antihypertensive drugs (including beta-blockers), lipid low-
ering drugs, antithyroid drugs, oral corticosteroids, and
estrogens/hormone replacement therapy (HRT). In addition,
a history of specific types of fractures was also considered:
pelvic, hip, femur, tibia, fibula, and vertebral fractures.
Data analysis
Chi-square tests for categorical variables and Student t tests
for continuous variables were used to assess the differences
between cases and controls. The incidence rate of diagnosis of
AF in the cohort of new users of BP was calculated as the
number of events occurring during follow-up divided by the
cumulative person-years of exposure in the study period. A
conditional logistic regression was performed to obtain the
odds ratio (OR) as an estimate of the relative risk of AF for
different BP exposure categories. ORs and 95 % CI were
calculated for current, recent, and past use of bisphosphonates,
Fig. 1 Flow chart of the
bisphosphonate cohort and case-
control selection process
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whether separately, overall, and or single compound, using
distant past use as the reference category. All of the po-
tential risk factors which were univariately associated with
the outcome (p<0.05) were considered to be potential
confounders and were included in the final multivariate
models.
In addition, the potential effect modification of all covari-
ates, including age and sex, were investigated. To rule out
possible outcome misclassification in a sensitivity analysis,
we excluded those patients who were treated with digoxin or
warfarin as proxy for AF prior to the study entry date. To
assess misclassifications of exposure, the effects of varying
carry-over periods of 30 to 90 days were evaluated. The sta-
tistical analyses were performed using SPSS 18.0 (SPSS, Inc.,
Chicago, IL). For all of the analyses, statistical significance
was set at p<0.05.
Results
Between July 1, 2003 and December 31, 2006, 171,040 new
users of BP were identified. Of these, 122,346 (71.5 %) were
retained in the final study cohort after considering the exclu-
sion criteria (Fig. 1). In the final cohort of BP users, 726
(0.6 %) cases of AF were identified in the follow-up study.
The incidence rate (IR) of AF diagnosis in the cohort of new
users of BP was 3.65 per 1,000 person-years (PYs) (95 % CI,
3.40–3.92) (Table 1). The incidence rate was higher in males
(4.59 per 1,000 PYs) than in females (3.51 per 1,000 PYs) and
increased with advancing age. After matching by age, sex, and
index date, 7,260 controls were identified.
The characteristics of the cases and controls are shown in
Table 2. Most participants were females (83.9 %) with a mean
age at cohort entry of 76.9±7.6 years. More than 60 % of
patients were over 75 years old. Cases were more likely to
be affected by cardiovascular diseases and to be treated with
lipid lowering drugs, oral corticosteroids, or antithyroid drugs
than with controls.
After adjustment for potential confounders, an increased
risk of AF among current users of BP was observed in com-
parison with those who had discontinued BP treatment for
more than 1 year prior to ID (OR, 1.78; 95 % CI, 1.46–
2.16). Using the same method of comparison, the risk of AF
also remained statistically significant in recent users of BP
(OR, 1.70; 95 % CI, 1.27–2.28) and past users of BP (OR,
1.41; 95 % CI, 1.07–185) (Table 3).
When stratifying by single compound use (Table 4), cur-
rent users of alendronate (OR, 1.97; 95 % CI, 1.59–2.43) in
combination with colecalciferol, and risedronate were associ-
ated with the highest risk of AF as compared with those who
had stopped BP more than 1 year prior to the study entry date.
No significant effect modifications for age and sex were
found. Furthermore, our main findings remained unchanged
in a sensitivity analysis that excluded patients with a prescrip-
tion of digoxin or warfarin before their cohort entry.
Discussion
To our knowledge, this is the first Italian multicenter study
exploring the risk of AF in association with BP exposure.
We found that current users of bisphosphonates are at a higher
risk of AF compared to those who had stopped BP treat-
ment at least 1 year before. However, a somewhat in-
creased risk was observed for those who had stopped BP
therapy within the prior year, suggesting that the biological
effect of bisphosphonates on the heart, underlying a possible
increase in AF risk, may persist for some time after the dis-
continuation of BP treatment. This finding is coherent with
pharmacokinetic studies showing that BP remains in the bone
Table 1 Incidence rates of atrial fibrillation per 1,000 person-years by sex and age in the Italian cohort of new users of bisphosphonates (n=122,346)
All Men Women
Age groups (years) Cases/py Incidence rate (95 % CI) Cases/py Incidence rate (95 % CI) Cases/py Incidence rate (95 % CI)
55–59 years 11/11,118 0.99 (0.53–1.71) 2/1455 1.37 (0.27–4.41) 9/9663 0.93 (0.46–1.7)
60–64 years 37/20,855 1.77 (1.27–2.42) 7/2606 2.69 (1.20–5.27) 30/18,249 1.64 (1.13–2.31)
65–69 years 72/31,766 2.27 (1.79–2.84) 17/3850 4.42 (2.67–6.91) 55/27,916 1.97 (1.5–2.54)
70–74 years 122/37,805 3.23 (2.7–3.84) 16/4597 3.48 (2.07–5.52) 106/33,208 3.19 (2.63–3.84)
75–79 years 215/41,326 5.20 (4.55–5.93) 42/5275 7.96 (5.82–10.65) 173/36,051 4.80 (4.12–5.55)
80–84 years 157/34,882 4.50 (3.84–5.25) 17/4731 3.59 (2.17–5.62) 140/30,151 4.64 (3.92–5.46)
85 years 112/21,119 5.30 (4.39–6.36) 16/2969 5.39 (3.21–8.54) 96/18,150 5.29 (4.31–6.43)
Total 726/198,871 3.65 (3.40–3.92) 117/25,483 4.59 (3.81–5.48) 609/173,388 3.51 (3.24–3.80)
Standardizeda 2.44(1.91-3.12)
py person-years, CI confidence interval
a Age—standardized incidence rate using World Health Organization reference population
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for years, potentially continuing to exert its effects on the bone
as well as on the heart [29–32].
A double-blind RTC concurrent multicenter study of post-
menopausal women with osteoporosis evaluated the effects of
alendronate over a 10-year period. The results showed that
patients who stopped alendronate at year 5 retained significant
BMD values above baseline values in the last year of the study
at lumbar spine, trochanter, total hip, and total body locations
[33]. This implies that BP can have effects on bone
composition even after the end of treatment. A study
of children exposed to oral pamidronate for a mean
period of 6.7 years demonstrated that after treatment
withdrawal, BP was detectable in their urine after an average
of almost 8 years [34].
Various bisphosphonates differ in terms of the mineral-
binding and cellular effects which may result in different clin-
ical effects [35, 36]. In our study, current users of alendronate
and risedronate had the highest increases in AF risk when
compared to those patients who had stopped bisphosphonates
for more than 1 year.
It is well known that observational studies cannot randomly
assign exposure, and this limitation can lead to confounding
effects because of different baseline risks for the exposure
categories. In general, patients who are treated with
bisphosphonates may have a higher baseline risk of AF com-
pared to those who are not treated. In our study, by choosing as
reference group those BP users who had stopped treatment
more than 1 year before, we attempted to minimize the effects
of confounding by indication. However, this possibility of risk
cannot be totally ruled out. Baseline risk can also differ be-
tween patients who stopped treatment versus those who con-
tinued with BP treatment. In comparison with other studies
using non-use of BP as the point of reference, our study is
likely to be much less affected by this type of confounding.
Although we could not address all possible confounders, we
adjusted the multivariate analyses for the most important con-
founding factors.
There exists a large body of evidence about the association
betweenAF and BP (Appendix 1). In particular, our results are
in line with the study by Abrahamsen et al. [11], which found
Table 2 Characteristics of cases
of atrial fibrillation and controls
*p<0.05 (significant)
a The data is mean± standard
deviation
Characteristics Cases
n=726
Percent Controls
n=7260
Percent p value
Gender, female 609 83.88 6090 83.88 –
Agea 76.9±7.64 76.9±7.65 –
Age categories
55–65 years 59 8.10 602 8.30
66–75 years 219 30.20 2155 29.70
76–85 years 361 49.70 3637 50.10
>85 years 87 12.00 866 11.90
Cardiovascular diseases
Angina pectoris 203 27.96 1215 19.95 <0.001*
Myocardial infarction 20 2.75 92 1.51 0.001*
Heart failure 80 11.02 199 3.27 <0.001*
Antihypertensive drugs 627 86.36 5186 85.16 <0.001*
Diabetes mellitus 84 11.57 780 12.81 0.494
Estrogen/hormone replace therapy 35 4.82 334 5.48 0.787
Any type of fractures 78 10.74 669 10.99 0.177
Prior use of drugs
Use of lipid lowering 181 24.93 1497 20.62 0.007*
Oral corticosteroids 271 37.33 2184 30.08 <0.001*
Antithyroid 18 2.48 87 1.20 0.004*
Table 3 Association between exposure to oral bisphosphonates and
atrial fibrillation
Cases
n=726 (%)
Controls
n=7260 (%)
Crude OR
(95 % CI)
Adjusted OR
(95 % CI)
Current 373 (51) 3129 (43) 1.71 (1.41–2.08) 1.78 (1.46–2.16)
Recent 78 (11) 667 (09) 1.68 (1.26–2.23) 1.70 (1.27–2.28)
Past 96 (13) 1006 (14) 1.38 (1.06–1.80) 1.41 (1.07–1.85)
Distant
past
179 (25) 2458 (34) Reference Reference
Adjusted for angina pectoris, heart failure, antihypertensive drugs, myocar-
dial infarction, use of lipid lowering drugs, oral corticosteroids, and anti-
thyroid drugs. Categories of users: current (0–90 days prior to index date),
recent (91–180 days), past (181–365 days), and distant past (365+days)
CI confidence interval, OR odds ratio
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an association between oral BP and AF in patients with frac-
tures (hazard ratio, 1.18; 95 % CI, 1.08–1.29). Similar results
were reported in a case-control study (BThe Group Health
study^), which documented higher AF risk for alendronate
users compared with non-users of BP (OR, 1.86; 95 % CI,
1.09–3.15). The patient characteristics were similar to those in
our study in terms of age and the burden of cardiovascular
diseases [13]. In line with our findings, a recent meta-
analysis of six observational studies (OR, 1.27; 95 % CI,
1.16–1.39) and six RCT (OR, 1.40; 95 % CI, 1.02–1.93) has
reported an increased risk of AF among users of BP [37].
On the contrary, a Danish study, using healthcare data-
bases, showed an association between the use of etidronate
and alendronate and AF that was not statistically significant
when compared to non-users of BP. [18]. It is possible that
differences in study design and different prescription patterns
for BP may account for the differences observed between the
Danish study and ours.
The biological mechanisms explaining possible increases
in the risk of AF in BP-treated patients is still unknown. It has
been suggested that parenteral administration of BP can trig-
ger inflammation via cytokines, which might lead to a broad
spectrum of cardiovascular effects including AF [14]. Another
study has suggested that alendronate-related changes of cyto-
kine production are mediated through the regulation of tran-
scriptional activity [38]. In addition, evidence from autopsies
has showed that long-term use of oral BP, such as alendronate
can lead to calcification in the conducting system and atria
[37]. A recent study [39] conducted on oral mucosa from
BP-treated patients reported a significantly elevated produc-
tion of cytokines (including IL-6). Interestingly, an in vitro
study showed that atrial and, to a lesser extent, ventricular
cardiomyocytes developed abnormalities in calcium dynamics
when exposed to alendronate [40].
In our study, some limitations have to be acknowledged:
the data sources of the study did not capture the use of
zoledronic acid, which is only intravenously adminis-
tered in hospitals in Italy. We used dispensing data to
evaluate the exposure status of the patients, and we had no
information about their actual use of the medications. If the
Table 4 Associations between atrial fibrillation and oral bisphosphonates by single compound
Cases
n=726 (%)
Controls
n=7260 (%)
Crude OR
(95 % CI)
Adjusted OR*
(95 % CI)
Current users (0–90 days)
Etidronate 0 (0.00) 7 (0.10) (NA) NA
Clodronate 4 (0.55) 34 (0.47) 1.66 (0.58–4.76) 1.68 (0.58–4.88)
Alendronate 255 (35.12) 1930 (26.58) 1.88 (1.53–2.31) 1.97 (1.59–2.43)
Risedronate 82 (11.29) 868 (11.96) 1.36 (1.03–1.79) 1.35 (1.01–1.79)
Neridronic acid 12 (1.65) 119 (1.64) 1.43 (0.77–2.66) 1.46 (0.78–2.75)
Alendronate plus colecalciferol 15 (2.07) 132 (1.82) 1.67 (0.94–2.96) 1.79 (1.00–3.21)
More than one BP within the same period of time. 5 (0.69) 39 (0.54) 1.83 (0.71–4.7) 2.07 (0.79–5.46)
Recent users (91–180 days)
Etidronate 0 (0.00) 6 (0.08) (NA) NA
Clodronate 3 (0.41) 12 (0.17) 3.42 (0.95–12.23) 4.12 (1.1–15.36)
Alendronate 44 (6.06) 420 (5.79) 1.50 (1.06–2.13) 1.49 (1.04–2.14)
Risedronate 20 (2.75) 165 (2.27) 1.76 (1.07–2.88) 1.87 (1.13–3.08)
Neridronic acid 1 (0.14) 43 (0.59) (NA) NA
Alendronate plus colecalciferol 7 (0.96) 16 (0.22) 6.72 (2.63–17.17) 6.63 (2.48–17.70)
More than one BP within the same period of time. 3 (0.41) 3 (0.04) 13.64 (2.73–68.12) 11.38 (2.24–57.73)
Past users (181–365 days)
Etidronate 0 (0.00) 6 (0.08) (NA) NA
Clodronate 1 (0.14) 16 (0.22) (NA) NA
Alendronate 63 (8.68) 635 (8.75) 1.44 (1.06–1.95) 1.46 (1.06–1.99)
Risedronate 28 (3.86) 251 (3.46) 1.62 (1.06–2.48) 1.63 (1.05–2.51)
Neridronic acid 2 (0.28) 76 (1.05) (NA) NA
Alendronate plus colecalciferol 0 (0.00) 13 (0.18) (NA) NA
More than one BP within the same period of time. 2 (0.28) 11 (0.15) (NA) NA
Distant past user of any BP>365 days 179 (24.66) 2458 (33.90) Reference Reference
Adjusted for angina pectoris,myocardial infarction, heart failure, antihypertensive drugs, use of lipid lowering drugs, oral corticosteroids, and antithyroid therapy
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exposure misclassification exists due to poor compliance, it is
however likely to be randomly distributed among the cases
and controls, eventually leading to an underestimation of the
true effects of BP. For some BP users, the exposure data were
too limited and did not allow for robust risk estimates.
Nevertheless, a wide range of BP use has been investigated,
and since the database network which was used in the study
comprises only information on hospital discharge diagnoses,
it is likely that we captured only the more severe cases of AF
that led to hospitalization, which in turn reduces the general-
izability of our findings.
We also excluded cancer patients because they are at a
higher risk of atrial fibrillation [41], and these patients are
difficult to trace by using administrative databases because
of their possibly long stays in hospitals and other institutions,
especially at advanced stages of the disease. Finally, cancer
patients who receive bisphosphonates for the treatment of
bone metastasis are generally treated in hospital with intrave-
nous administrations of zoledronic acid and, as such, the use
of this drug cannot be captured using our data sources, which
were available only for outpatient prescriptions. For this rea-
son, exposure to bisphosphonates in cancer patients would
likely be misclassified, and we therefore preferred not to in-
clude these patients in the study, even if this decision limited
the generalizability of our results.
We did not validate the AF cases because according to
Jensen et al. [42], the ICD-9 code 427.31 performs well in
identifying AF in electronic health databases. Jensen’s study
evaluated 16 studies, of which 14 were comparable and
yielded a positive predictive value (PPV) that was between
70 and 96 %. In addition, the exclusion of patients who were
treated with digoxin and warfarin (as proxies of AF) did not
change the main risk estimates, ruling out major effects of
outcome misclassifications in the observed findings.
Current guidelines for the use of bisphosphonates do not
specify to have early control for possible AF. However, we
acknowledge that a standard clinical evaluation of the patients
at the beginning of BP treatment may occasionally lead to
diagnosis of hitherto hidden AF. The potential surveillance
bias was however minimized in our study by conducting a
case-control study nested in a cohort of new users of BP.
In conclusion, our results suggest that the use of
bisphosphonates is associated with an almost double increase
in the risk of AF when our population is compared to those
who had stopped BP treatment before at least 1 year. This risk
is especially elevated for current users of alendronate and
risedronate. Moreover, the risk seems not to disappear imme-
diately after stopping BP therapy, which may suggest either
long-term effects of BP due to bone accumulation and slow
release in the blood, or confounding by indication.
Acknowledgments The authors are very grateful to Dr. Lilith Haynes
for the time devoted to review and edit our manuscript.
Conflicts of interest The study was supported by Agenzia Italiana del
Farmaco (AIFA - grant FARM06R9YY), Rome, Italy. Dr. Schuemie
joined Janssen Research & Development since completing the research
described here. Lizbeth Herrera, Ingrid Leal, Francesco Lapi, Giampiero
Mazzaglia, Vincenzo Arcoraci, Francesco Cipriani, Emiliano Sessa,
Alberto Vaccheri, Carlo Piccinni, Tommaso Staniscia, Annarita Vestri,
Mauro Di Bari, Giovanni Corrao, Antonella Zambon, Dario Gregori,
Flavia Carle, Miriam Sturkenboom, and Gianluca Trifiro declare that they
have no conflict of interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and the source are credited.
References
1. Recker RR, Lewiecki EM, Miller PD, Reiffel J (2009) Safety of
bisphosphonates in the treatment of osteoporosis. Am J Med 122(2
Suppl):S22–S32
2. Boonen S (2009) Impact of treatment efficacy and dosing frequency
on cost-effectiveness of bisphosphonate treatment for osteoporosis: a
perspective. Curr Med Res Opin 25(10):2335–2341
3. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB,
Kendler D, Eriksen EF, Mesenbrink PG, Eastell R (2009) Effects of
yearly zoledronic acid 5 mg on bone turnover markers and relation of
PINP with fracture reduction in postmenopausal women with osteo-
porosis. J Bone Miner Res 24(9):1544–1551
4. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L,
Hanley DA, Kendler DL, Yuen CK, Lewiecki EM (2013)
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug
holiday. Am J Med 126(1):13–20
5. Jansen JP, Bergman GJ, Huels J, Olson M (2011) The efficacy of
bisphosphonates in the prevention of vertebral, hip, and nonvertebral-
nonhip fractures in osteoporosis: a network meta-analysis. Semin
Arthritis Rheum 40 (4):275–284 e271-272
6. Pazianas M, Cooper C, Ebetino FH, Russell RG (2010) Long-term
treatment with bisphosphonates and their safety in postmenopausal
osteoporosis. Ther Clin Risk Manag 6:325–343
7. van Boven JF, de Boer PT, Postma MJ, Vegter S (2013) Persistence
with osteoporosis medication among newly-treated osteoporotic pa-
tients. J Bone Miner Metab
8. Solomon DH, Rekedal L, Cadarette SM (2009) Osteoporosis treat-
ments and adverse events. Curr Opin Rheumatol 21(4):363–368
9. Rizzoli R, Reginster JY, Boonen S, Breart G, Diez-Perez A,
Felsenberg D, Kaufman JM, Kanis JA, Cooper C (2011) Adverse
reactions and drug-drug interactions in the management of women
with postmenopausal osteoporosis. Calcif Tissue Int 89(2):91–104
10. Abrahamsen B (2010) Bisphosphonate adverse effects, lessons from
large databases. Curr Opin Rheumatol 22(4):404–409
11. Abrahamsen B, Eiken P, BrixenK (2009) Atrial fibrillation in fracture
patients treated with oral bisphosphonates. J Intern Med 265(5):
581–592
12. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA,
Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P,
Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF,
Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zole-
dronic acid for treatment of postmenopausal osteoporosis. N Engl J
Med 356(18):1809–1822
Osteoporos Int (2015) 26:1499–1506 1505
13. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (2008) Use
of alendronate and risk of incident atrial fibrillation in women. Arch
Intern Med 168(8):826–831
14. Cummings SR, Schwartz AV, Black DM (2007) Alendronate and
atrial fibrillation. N Engl J Med 356(18):1895–1896
15. John Camm A (2010) Review of the cardiovascular safety of zole-
dronic acid and other bisphosphonates for the treatment of osteopo-
rosis. Clin Ther 32(3):426–436
16. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-
Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC,
Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of
alendronate on risk of fracture in women with low bone density but
without vertebral fractures: results from the Fracture Intervention
Trial. JAMA 280(24):2077–2082
17. Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR (2010)
Osteoporosis treatment and atrial fibrillation: alendronate versus ral-
oxifene. Menopause 17(1):57–63
18. Sorensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD,
Cummings SR, Baron JA (2008) Use of bisphosphonates among
women and risk of atrial fibrillation and flutter: population based
case-control study. BMJ 336(7648):813–816
19. Rhee CW, Lee J, Oh S, Choi NK, Park BJ (2012) Use of bisphos-
phonate and risk of atrial fibrillation in older women with osteopo-
rosis. Osteoporos Int 23(1):247–254
20. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L,
Mosekilde L (2010) Risk of atrial fibrillation associated with
use of bisphosphonates and other drugs against osteoporosis:
a cohort study. Calcif Tissue Int 86(5):335–342
21. Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD,
Crandall BG, Weiss JP, Lappe DL, Osborn JS, Day JD (2009)
Relation of bisphosphonate therapies and risk of developing atrial
fibrillation. Am J Cardiol 103(6):824–828
22. Administration UFaD (2007) Update of Safety Review Follow-up to
the October 1, 2007 Early Communication about the Ongoing Safety
Review of Bisphosphonates. http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/
DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm.
Accessed 07-23-2013 2013
23. Ringborg A, Nieuwlaat R, Lindgren P, Jonsson B, Fidan D,Maggioni
AP, Lopez-Sendon J, Stepinska J, Cokkinos DV, Crijns HJ (2008)
Costs of atrial fibrillation in five European countries: results from the
Euro Heart Survey on atrial fibrillation. Europace 10(4):403–411
24. Heeringa J (2010) Atrial fibrillation: is the prevalence rising?
Europace 12(4):451–452
25. Camm AJ, Camm CF, Savelieva I (2012) Medical treatment of atrial
fibrillation. J Cardiovasc Med (Hagerstown) 13(2):97–107
26. Camm AJ (2012) Atrial fibrillation and risk. Clin Cardiol
35(Suppl 1):1–2
27. Lapi F, Cipriani F, Caputi AP, Corrao G, Vaccheri A, Sturkenboom
MC, Di Bari M, Gregori D, Carle F, Staniscia T, Vestri A, Brandi M,
Fusco V, Campisi G, Mazzaglia G (2013) Assessing the risk of
osteonecrosis of the jaw due to bisphosphonate therapy in the sec-
ondary prevention of osteoporotic fractures. Osteoporos Int J
Established Result Cooperation Between Eur Found Osteoporos
Natl Osteoporos Found U S A 24(2):697–705
28. Beaumont JJ, Steenland K, Minton A, Meyer S (1989) A computer
program for incidence density sampling of controls in case-control
studies nested within occupational cohort studies. Am J Epidemiol
129(1):212–219
29. Watts NB, Diab DL (2010) Long-term use of bisphosphonates in
osteoporosis. J Clin Endocrinol Metab 95(4):1555–1565
30. Salari P, Abdollahi M (2012) Long term bisphosphonate use in oste-
oporotic patients; a step forward, two steps back. J Pharm Pharm Sci
15(2):305–317
31. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L,
Hanley DA, Kendler DL, Yuen CK, Lewiecki EM (2013)
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug
holiday. Am J Med 126(1):13–20
32. Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for
osteoporosis—where do we go from here? N Engl J Med 366(22):
2048–2051
33. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino
RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC,
Liberman UA (2004) Ten years’ experience with alendronate for
osteoporosis in postmenopausal women. N Engl J Med 350(12):
1189–1199
34. Papapoulos SE, Cremers SC (2007) Prolonged bisphosphonate re-
lease after treatment in children. N Engl J Med 356(10):1075–1076
35. Russell RG (2007) Bisphosphonates: mode of action and pharmacol-
ogy. Pediatrics 119(Suppl 2):S150–S162
36. Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49(1):
2–19
37. Sharma A, Chatterjee S, Arbab-Zadeh A, Goyal S, Lichstein E,
Ghosh J, Aikat S (2013) Risk of serious atrial fibrillation and stroke
with use of bisphosphonates: evidence from a meta-analysis. Chest
38. Tamai R, Sugiyama A, Kiyoura Y (2011) Alendronate regulates cy-
tokine production induced by lipid A through nuclear factor-kappaB
and Smad3 activation in human gingival fibroblasts. J Periodontal
Res 46(1):13–20
39. Mozzati M, Martinasso G, Maggiora M, Scoletta M, Zambelli M,
Carossa S, Oraldi M, Muzio G, Canuto RA (2013) Oral mucosa
produces cytokines and factors influencing osteoclast activity and
endothelial cell proliferation, in patients with osteonecrosis
of jaw after treatment with zoledronic acid. Clin Oral Investig
17(4):1259–1266
40. Kemeny-Suss N, Kasneci A, Rivas D, Afilalo J, Komarova
SV, Chalifour LE, Duque G (2009) Alendronate affects calci-
um dynamics in cardiomyocytes in vitro. Vasc Pharmacol
51(5–6):350–358
41. Farmakis D, Parissis J, Filippatos G (2014) Insights into onco-cardi-
ology: atrial fibrillation in cancer. J AmColl Cardiol 63(10):945–953
42. Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S
(2012) A systematic review of validated methods for identifying atri-
al fibrillation using administrative data. Pharmacoepidemiol Drug Saf
21(Suppl 1):141–147
1506 Osteoporos Int (2015) 26:1499–1506
